EP2744915A1 - Utilisation de ccne2 comme marqueur de stratification dans le traitement de tumeurs du sein avec de nouveaux inhibiteurs de kinases cycline-dépendantes (cdk) pan - Google Patents

Utilisation de ccne2 comme marqueur de stratification dans le traitement de tumeurs du sein avec de nouveaux inhibiteurs de kinases cycline-dépendantes (cdk) pan

Info

Publication number
EP2744915A1
EP2744915A1 EP12766598.2A EP12766598A EP2744915A1 EP 2744915 A1 EP2744915 A1 EP 2744915A1 EP 12766598 A EP12766598 A EP 12766598A EP 2744915 A1 EP2744915 A1 EP 2744915A1
Authority
EP
European Patent Office
Prior art keywords
determined
treatment
cyclin
nci
expression level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12766598.2A
Other languages
German (de)
English (en)
Inventor
Gerhard Siemeister
Philip Groth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH
Publication of EP2744915A1 publication Critical patent/EP2744915A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • CC E2 as a stratification marker in the treatment of breast tumors with new pan-CDK inhibitors
  • the invention relates to the use of CCNE2 as a stratification marker in the treatment of breast tumors with novel pan-CDK inhibitors
  • the eukaryotic cell division cycle ensures the duplication of the genome and its distribution to the daughter cells by undergoing a coordinated and regulated sequence of events.
  • the cell cycle is divided into four consecutive phases: the Gl phase represents the time before DNA replication in which the cell grows. In the S phase, the cell replicates its DNA, and in the G2 phase, it prepares for entry into mitosis. In mitosis (M phase), the replicated DNA is separated and cell division is performed.
  • CDKs cyclin-dependent kinases
  • CDK / Cyc pairs are active in the different phases of the cell cycle.
  • important CDK / Cyc pairs are, for example, CDK4 (6) / CycD, CDK2 / CycE, CDK2 / CycA, CDK1 / CycA and CDK1 / CycB.
  • the activities of the CDK4 (6) / CycD and CDK2 / CycE complexes drive the entry of a cell into the cell cycle and undergo the "restriction point" which marks the independence of a cell from further growth signals to complete the initiated cell division ,
  • a number of control mechanisms ensure the orderly course of cell division phases and the correct distribution of the duplicated genetic material to the daughter cells.
  • the activity of the CDKs is influenced by inhibitory proteins, such as p21, p16, or p27, and the expression and degradation of the cyclins are regulated.
  • the proteins of the spindle assembly checkpoint ensure correct attachment of the spindle apparatus to the duplicated chromosomes during the mitosis phase of the cell division cycle and ensure a correct distribution of the chormosomes on the daughter cells.
  • Key proteins of the spindle assembly checkpoint are MAD1, MAD2, BUBI, BUBR1, TTK (Mps-1) and cdc20. In human cells, there are two isoforms of the MAD2 protein, MAD2L1 and MAD2L2 (MAD2B).
  • CDK inhibitors have been in clinical development for more than 10 years, no biomarkers have yet been described that allow predicting a patient's response to CDK inhibitor therapy. Such stratification markers allow targeted therapy of those patients who are likely to benefit from CDK inhibitor therapy. In addition, the probability of success of clinical trials increases by stratification markers.
  • WO2010 / 046035 discloses particularly effective pan-CDK inhibitors of the formula (I)
  • X is -O- or -NH-
  • R 1 is a methyl, ethyl, propyl or isopropyl group
  • R 2 and R 3 independently of one another are hydrogen, a methyl or ethyl group, and R is a C 1 -C 6 -alkyl group or a C 3 -C 7 -cycloalkyl ring,
  • a C 1 -C 6 -alkyl group is to be understood as meaning in each case a straight-chain or branched alkyl radical, such as, for example, a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec. Butyl, tert. Butyl, pentyl, isopentyl or a hexyl radical.
  • a straight-chain or branched alkyl radical such as, for example, a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec. Butyl, tert. Butyl, pentyl, isopentyl or a hexyl radical.
  • a C3-C7-cycloalkyng is to be understood as meaning a cyclopropyl-cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl ring.
  • X may be -O- or -NH-.
  • X is -0-.
  • R 1 may represent a methyl, ethyl, propyl or isopropyl group.
  • R 1 is a methyl group.
  • R 2 and R 3 may independently represent hydrogen, a methyl or ethyl group.
  • R 2 and R 3 independently represent hydrogen or a methyl group.
  • R 2 is a methyl group and R 3 is hydrogen or a methyl group.
  • R 4 may represent a Ci-C ö -Alkyhest or a C3-C7 cycloalkyl.
  • R 4 is a methyl or ethyl group or a cyclopropyl ring.
  • R 4 is a methyl or ethyl group or a cyclopropyl ring.
  • R 4 is a compound (2R, 3R) -3 - ⁇ [2 - ⁇ [4- (R -cyclopropylsulfonimidoyl) phenyl] amino ⁇ -5- (trifluoromethyl) pyrimidin-4-yl] oxy ⁇ butan-2-ol ( Compound A).
  • the object of the present invention is, for the pan-CDK inhibitors of WO2010 / 046035, especially for (2R, 3R) -3 - ⁇ [2 - ⁇ [4- (S-cyclopropylsulfonimidoyl) phenyl] amino ⁇ -5- (trifluoromethyl) pyrimidin-4-yl] oxy ⁇ butan-2-ol (Compound A ) to find a stratification marker.
  • CCNE2 is suitable as a stratification marker for human breast tumor cells in the treatment with the new pan-CDK inhibitors of WO2010 / 046035, in particular in the treatment with the compound A and is able to predict the sensitivity.
  • the method according to the invention comprises a determination of the CCNE2 expression as a marker for the sensitivity of tumor cells or of tumors to the treatment with a CDK inhibitor.
  • a quantitative determination is preferably carried out, the expression level of CCNE2 being determined at the nucleic acid level and / or at the protein level in the tumor tissue or in tumor cells and optionally compared with the expression level in the surrounding normal tissue.
  • the expression level of CCNE2 can be determined by standard methods. In a preferred embodiment, a determination at the nucleic acid level, e.g. a determination of the amount of transcript performed.
  • quantitative determinations of nucleic acid level CCNE2 expression may include hybridization with labeled for CCNE2-specific probes, nucleic acid amplification reactions, gene-chip hybridizations, and / or transcript sequencing. Preferred determination methods are quantitative PCR or real-time PCR. Protein level quantitative determinations may include immunological detection methods using anti-CCNE2 antibodies, for example in Western blot or ELISA format.
  • the sample in which CCNE2 expression is to be determined can be derived, for example, from a cell culture or an organism, eg a mammal, in particular a human, but also from an experimental animal. Particularly preferably, a determination is carried out on a sample which originates from a culture of tumor cells, in particular of human tumor cells, or from a tumor patient, in particular a human patient or a test animal for tumor research.
  • the sample may originate from the tumor itself or from detached tumor cells, eg circulating tumor cells from body fluids, eg blood.
  • the method according to the invention for therapy selection (therapy decision, stratification) in the treatment of a patient can be used in the context of a therapy method.
  • the method according to the invention can be used in the treatment of an experimental animal in the context of the identification or / and characterization of new active substances.
  • the method can be carried out in a cell culture, for example in the context of screening processes.
  • the method includes one or more determinations.
  • a determination of the expression of CCNE2 in a sample of the cell culture or organism to be tested is performed prior to the initial administration of the CDK inhibitor.
  • This assay was used for the following cell lines: MCF 10A, SK-BR-3, MCF7, HCT 116, HT-29, SW480, Caco-2, MIAPaCa-2, DU145, PC3, HeLa, Caki2, 786-0, A -375, NCI-H460, NCI-H69, NCI-H1975, A549.
  • Cultured human tumor cells (originally purchased from the ATCC, HeLa-MaTu and HeLa-MaTu-ADR, originally obtained from Epo GmbH, Berlin) were in a density of 1000 to 5000 cells / measurement point, depending on the growth rate of the cell line in a 96 -Hole multi-well plate in 200 ⁇ growth medium (DMEM / HAMS F12, 2 mM L-glutamine, 10% fetal calf serum) plated.
  • DMEM / HAMS F12, 2 mM L-glutamine, 10% fetal calf serum 200 ⁇ growth medium
  • the cells of one plate were stained with crystal violet (see below), while the medium of the other plates by fresh culture medium (200 ⁇ ), the test substances in various concentrations (0 ⁇ , and in the range - 30 ⁇ , the final concentration of the solvent dimethylsulfoxide was 0.5%) were added replaced.
  • the cells were incubated for 4 days in the presence of the test substances.
  • the cell proliferation was determined by staining the cells with crystal violet: The cells were fixed by adding 20 ⁇ measuring point of a 1 l% glutaraldehyde solution for 15 min at room temperature. After washing the fixed cells three times with water, the plates were dried at room temperature.
  • This assay was used for the following cell lines: KPL-1, MDA-MB-453, Hs 578T, MDA-MB-231, MCF 10A, MDA-MB-468, ZR-75-1, T ⁇ 7D, MDA-MB -435s, DL 475, BT-20, BT-474, EVSA-T, BT-549, NCI-H460, NCI-H810, NCI-H441, NCI-H1838, NCI-H69, NCI-H2030, NCI-H358, NCI-H1793, NCI-H1048, SK-MES-1, NCI-H2347, NCI-H1975, A549, NCI-H23, NCI-H2170, NCI-H2228, NCI-H661, NCI-H1703, NCI-H1581, NCI H226, NCI-H1563, NCI-H522, ChaGo-K-1, NCI-H1437. Inhibition of cell proliferation by Compound A was determined
  • This assay was used to determine the relative level of mRNA in the tumor cell lines used.
  • RNA concentration was determined by measuring the optical density at 260 and 280 nm.
  • a quality control of the RNA was performed on an Agilent Bioanalyzer. For further analysis, only RNA with a ratio of 28S / 18S rRNA greater than 1.0 was used.
  • RNA samples were used for the synthesis of double-stranded cDNA using the One-Cycle cDNA Synthesis Kit (Affymetrix) in the presence of a T7-01igo (dT) 24 DNA oligonucleotide primer according to the manufacturer's instructions.
  • the cDNA was purified using the Affymetrix GeneChip Sample Cleanup module.
  • the purified cDNA was then transcribed in vitro using the GeneChip IVT labeling kit (Affymetrix) in the presence of biotinylated ribonucleotides to give biotin-labeled cRNA.
  • the labeled cRNA was then purified using the GeneChip Sample Cleanup Module (Affymetrix).
  • the labeled cRNA was quantified by measuring the optical density at 260 and 280 nm and subjected to a quality control on the Agilent Bioanalyzer.
  • the array was then scanned at 570 nm using a confocal laser scanner (GeneChip-3000 Scanner, Affymetrix) and converted to quantitative single values (1 value per signal, 40 individual values per gene) using the Affymetrix GeneChip software.
  • the individual values were combined into one value per gene using an implementation of the Affymetrix MAS5 algorithm from Genedata REFINER®.
  • the procedure is repeated using three microarrays (replicates) for each of the cell lines.
  • the resulting individual values of all genes and replicates were normalized to the median of all values.
  • Each value per gene and replicate was then summarized by calculation of the harmonic mean to a value per gene and cell line.
  • the Pearson correlation coefficient between gene and test substance was calculated for all cell lines.
  • Compound A was tested in the cell lines of Table 1, which exemplify the indicated sub-indications.
  • Table 2 listed 62 genes that encode proteins that have a regulatory function in the human body
  • CDK1 983 cyclin-dependent kinase 1
  • CDK2 1017 cyclin-dependent kinase 2
  • CDK3 1018 cyclin-dependent kinase 3
  • CDK4 1019 cyclin-dependent kinase 4
  • CDK6 1021 cyclin-dependent kinase 6
  • CDK7 1022 cyclin-dependent kinase 7
  • CDKN2C 1031 cyclin-dependent kinase inhibitor 2C (pI8)
  • CDKN3 1033 cyclin-dependent kinase inhibitor 3
  • MAD1L1 8379 MAD1 mitotic arrest deficient-like 1
  • Table 3 shows the results from the proliferation assays.
  • NCI-H810 non-small cell lung carcinoma 9.01
  • NCI-H661 non-small cell lung carcinoma 53.1
  • NCI-H1563 non-small cell lung carcinoma
  • NCI-H1437 non-small cell lung carcinoma
  • Table 4 shows the relative mRNA levels of the 62 cell cycle regulatory genes in the 51 cell lines studied in affymetrix gene-chip hybridization studies. Tab. 4
  • the sensitivity of 51 human tumor cell lines to compound A was determined in proliferation assays.
  • the calculated IC50 values were correlated with the relative mRNA levels of 62 cell cycle regulatory proteins determined in independent genechip hybridization studies (Affymetrix technology).
  • Genes for which statistically significant correlations (P ⁇ 0.05) were found within the breast tumor cell lines are summarized in Table 5.
  • the correlation coefficients and significances were calculated using Microsoft Excel 2003 and SigmaStat 3.0.
  • FIG. 1 Graphical representation of the sensitivity of the human breast tumor cell lines to the
  • Compound A is determined to be IC 50 [nM] in proliferation assays against the relative mRNA level of the CCNE2 gene.
  • the solid line represents the correlation line.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne l'utilisation de CCNE2 comme marqueur de stratification dans le traitement de tumeurs du sein avec de nouveaux inhibiteurs de kinases cycline-dépendantes (CDK) pan de formule (I).
EP12766598.2A 2011-08-16 2012-08-15 Utilisation de ccne2 comme marqueur de stratification dans le traitement de tumeurs du sein avec de nouveaux inhibiteurs de kinases cycline-dépendantes (cdk) pan Withdrawn EP2744915A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011080991A DE102011080991A1 (de) 2011-08-16 2011-08-16 Verwendung von CCNE2 als Stratifikationsmarker bei der Behandlung von Brusttumoren mit neuen pan-CDK-Inhibitoren
PCT/EP2012/065947 WO2013024118A1 (fr) 2011-08-16 2012-08-15 Utilisation de ccne2 comme marqueur de stratification dans le traitement de tumeurs du sein avec de nouveaux inhibiteurs de kinases cycline-dépendantes (cdk) pan

Publications (1)

Publication Number Publication Date
EP2744915A1 true EP2744915A1 (fr) 2014-06-25

Family

ID=46963669

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12766598.2A Withdrawn EP2744915A1 (fr) 2011-08-16 2012-08-15 Utilisation de ccne2 comme marqueur de stratification dans le traitement de tumeurs du sein avec de nouveaux inhibiteurs de kinases cycline-dépendantes (cdk) pan

Country Status (13)

Country Link
US (1) US20140221243A1 (fr)
EP (1) EP2744915A1 (fr)
JP (1) JP2014524250A (fr)
KR (1) KR20140044911A (fr)
CN (1) CN103732762A (fr)
AU (1) AU2012296839A1 (fr)
BR (1) BR112014003096A2 (fr)
CA (1) CA2845324A1 (fr)
DE (1) DE102011080991A1 (fr)
EA (1) EA201490411A1 (fr)
IL (1) IL230781A0 (fr)
MX (1) MX2014001810A (fr)
WO (1) WO2013024118A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011080992A1 (de) * 2011-08-16 2013-02-21 Bayer Pharma AG Verwendung von MAD2L2 als Stratifikationsmarker bei der Behandlung von Brusttumoren mit neuen pan-CDK-Inhibitoren
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020205560A1 (fr) 2019-03-29 2020-10-08 Incyte Corporation Composés sulfonylamides utilisés comme inhibiteurs de la cdk2
MX2022004390A (es) 2019-10-11 2022-08-08 Incyte Corp Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2).
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056762A2 (fr) * 1999-03-22 2000-09-28 Novozymes Biotech, Inc. Methodes de surveillance de l'expression genique multiple
EP1717232A1 (fr) * 2005-04-28 2006-11-02 Bayer CropScience GmbH Urées phénylsulfonyles ayant une activité herbicide
EP1803723A1 (fr) * 2006-01-03 2007-07-04 Bayer Schering Pharma Aktiengesellschaft Dérivés (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximide en tant qu'inhibiteurs de la kinase aurora pour le traitement de cancer
DE102006027156A1 (de) * 2006-06-08 2007-12-13 Bayer Schering Pharma Ag Sulfimide als Proteinkinaseinhibitoren
DE102006041382A1 (de) * 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
EP1939185A1 (fr) * 2006-12-20 2008-07-02 Bayer Schering Pharma Aktiengesellschaft Nouveaux hetaryl-phénylènediamine-pyrimidines en tant qu'inhibiteurs de protéine kinase pour le traitement du cancer
ITBO20080429A1 (it) * 2008-07-08 2010-01-09 Paolo Amadesi Impianto per la riduzione dell'anidride carbonica contenuta nei fumi di combustione.
EP2350317A4 (fr) * 2008-10-20 2012-06-27 Univ Colorado Regents Marqueurs biologiques prédictifs d une réponse anticancéreuse à des inhibiteurs de récepteur kinase de facteur de croissance 1 de type insuline
EP2179991A1 (fr) * 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Dérivés d'anilino-pyrimidine substitués par sulfoximine en tant qu'inhibiteurs de CDK, leur fabrication et leur utilisation en tant que médicaments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2013024118A1 *

Also Published As

Publication number Publication date
JP2014524250A (ja) 2014-09-22
CA2845324A1 (fr) 2013-02-21
KR20140044911A (ko) 2014-04-15
EA201490411A1 (ru) 2014-07-30
US20140221243A1 (en) 2014-08-07
WO2013024118A1 (fr) 2013-02-21
MX2014001810A (es) 2014-03-31
AU2012296839A1 (en) 2014-02-27
DE102011080991A1 (de) 2013-02-21
CN103732762A (zh) 2014-04-16
IL230781A0 (en) 2014-03-31
BR112014003096A2 (pt) 2017-02-21

Similar Documents

Publication Publication Date Title
Bui et al. Genomics of clear-cell renal cell carcinoma: a systematic review and meta-analysis
WO2013024118A1 (fr) Utilisation de ccne2 comme marqueur de stratification dans le traitement de tumeurs du sein avec de nouveaux inhibiteurs de kinases cycline-dépendantes (cdk) pan
Buck et al. Detection of S-phase cell cycle progression using 5-ethynyl-2′-deoxyuridine incorporation with click chemistry, an alternative to using 5-bromo-2′-deoxyuridine antibodies
Brekke et al. Genomic changes in chromosomes 10, 16, and X in malignant peripheral nerve sheath tumors identify a high-risk patient group
EP1532444B1 (fr) Methode d'analyse de liquides organiques pour rechercher d'eventuelles cellules cancereuses et kits d'analyse correspondants
Bilge et al. Investigation of the interaction between anticancer drug ibrutinib and double-stranded DNA by electrochemical and molecular docking techniques
DE60117555T2 (de) Bewertungssystem für die vorhersage von krebsrezidiven
US20130274127A1 (en) Gene expression markers for prediction of response to phosphoinositide 3-kinase inhibitors
EP2744914B1 (fr) Utilisation de mad2l2 comme marqueur de stratification dans le traitement de tumeurs du sein avec de nouveaux inhibiteurs de kinases cycline-dépendantes (cdk) pan
CN102959090B (zh) 用于表征和鉴别遗传毒性化合物的基因表达分析
DE60009530T2 (de) Genetische toxizitätsmarker, herstellung und verwendung
CN104651522A (zh) I型胶原α1链的新应用
CA2707729A1 (fr) Biomarqueurs pour suivre le traitement par des composes quinazolinone
Šutić et al. Transcriptomic Profiling for Prognostic Biomarkers in Early-Stage Squamous Cell Lung Cancer (SqCLC)
Ulleryd et al. RNA sequencing data describing transcriptional changes in aorta of ApoE-/-mice after alpha 7
Campbell et al. Leveraging spatial profiling combined with bulk RNA sequencing to study patient-specific immunotherapeutic mechanisms
WO2010013633A1 (fr) Procédés de prédiction de l'état rb et de la sensibilité à l'inhibiteur de plk1 d'une cellule
DE102018112644A1 (de) CXCR3 als epigenetischer Marker zur Identifizierung von inflammatorischen Immunzellen, insbesonder CD8+ Gedächnis-T-Zellen
EP1658380A2 (fr) Procede pour determiner des marqueurs de cycle capillaire
Wu Molecular mechanisms and pharmacogenomics of constituents of Salvia miltiorrhiza for anticancer therapy
Lanciotti et al. Gene expression profiling: a possible tool in the prediction of outcome in paediatric acute lymphoblastic leukaemia?
DE102017125013A1 (de) MCC als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere basophiler Granulozyten
DE102017125019A1 (de) PDCD1 als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere PD1+ Zellen
Lee et al. Genomewide transcription profiles altered by BMI-1026 and Roscovitine and its implication in cellular senescence
WO2015059156A1 (fr) Procédé pour déterminer l'efficacité et/ou la spécificité d'un principe actif

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140317

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20160608